Related Experiment Video
Updated: May 26, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Soluble guanylate cyclase as a direct target for pharmacologic mitigation of chronic kidney disease
1Unit of Cardiovascular and Renal Research, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Abstract:
In a preclinical rat study, Lichtenberger et al. show that BAY-60-2770, a drug that activates soluble guanylyl cyclase, often rendered inactive by oxidative stress, mitigates kidney inflammation, injury, and fibrosis, likely by vascular effects after ischemia-reperfusion. Kidney perfusion, overall vascular reactivity, and medullary microvascular diameter are improved by the drug at doses that do not alter blood pressure. Soluble guanylyl cyclase is an attractive and potentially unexploited target to halt progression of chronic kidney disease.
Related Concept Videos
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
GPCRs Regulate Adenylyl Cylase Activity
Hormonal Regulation
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

